TY - JOUR AU - Mitsudomi, T. AU - Morita, S. AU - Yatabe, Y. AU - Negoro, S. AU - Okamoto, I. AU - Tsurutani, J. PY - 2010 DA - 2010// TI - Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70364-X DO - 10.1016/S1470-2045(09)70364-X ID - Mitsudomi2010 ER - TY - JOUR AU - Inoue, A. AU - Kobayashi, K. AU - Maemondo, M. AU - Sugawara, S. AU - Oizumi, S. AU - Isobe, H. PY - 2013 DA - 2013// TI - Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mds214 DO - 10.1093/annonc/mds214 ID - Inoue2013 ER - TY - JOUR AU - Yang, J. C. H. AU - Wu, Y. L. AU - Schuler, M. AU - Sebastian, M. AU - Popat, S. AU - Yamamoto, N. PY - 2015 DA - 2015// TI - Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6): analysis of overall survival data from two randomised, phase 3 trials JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71173-8 DO - 10.1016/S1470-2045(14)71173-8 ID - Yang2015 ER - TY - JOUR AU - Kobayashi, S. AU - Boggon, T. J. AU - Dayaram, T. AU - Jänne, P. A. AU - Kocher, O. AU - Meyerson, M. PY - 2005 DA - 2005// TI - EGFR mutation and resistance of non–small-cell lung Cancer to Gefitinib JO - N Engl J Med VL - 352 UR - https://doi.org/10.1056/NEJMoa044238 DO - 10.1056/NEJMoa044238 ID - Kobayashi2005 ER - TY - STD TI - Sequist L V., Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26. https://doi.org/10.1126/scitranslmed.3002003 ID - ref5 ER - TY - JOUR AU - Goss, G. AU - Tsai, C. M. AU - Shepherd, F. A. AU - Bazhenova, L. AU - Lee, J. S. AU - Chang, G. C. PY - 2016 DA - 2016// TI - Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study JO - Lancet Oncol. VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30508-3 DO - 10.1016/S1470-2045(16)30508-3 ID - Goss2016 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. -. L. AU - Ahn, M. -. J. AU - Garassino, M. C. AU - Kim, H. R. AU - Ramalingam, S. S. PY - 2017 DA - 2017// TI - Osimertinib or platinum-Pemetrexed in EGFR T790M-positive lung Cancer JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1612674 DO - 10.1056/NEJMoa1612674 ID - Mok2017 ER - TY - JOUR AU - Reckamp, K. L. AU - Melnikova, V. O. AU - Karlovich, C. AU - Sequist, L. PY - 2016 DA - 2016// TI - A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma JO - J Clin Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.05.035 DO - 10.1016/j.jtho.2016.05.035 ID - Reckamp2016 ER - TY - JOUR AU - Mak, K. S. AU - Bommel, A. C. M. AU - Stowell, C. AU - Abrahm, J. L. AU - Baker, M. AU - Baldotto, C. S. PY - 2016 DA - 2016// TI - Defining a standard set of patient-centred outcomes for lung cancer JO - Eur Respir J VL - 48 UR - https://doi.org/10.1183/13993003.02049-2015 DO - 10.1183/13993003.02049-2015 ID - Mak2016 ER - TY - JOUR AU - Luo, J. AU - Shen, L. AU - Zheng, D. PY - 2014 DA - 2014// TI - Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis JO - Sci Rep VL - 4 UR - https://doi.org/10.1038/srep06269 DO - 10.1038/srep06269 ID - Luo2014 ER - TY - STD TI - Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 2009;6:e1000097. https://doi.org/10.1371/journal.pmed.1000097. ID - ref11 ER - TY - BOOK AU - Samson, D. AU - Schoelles, K. M. PY - 2012 DA - 2012// TI - Developing the topic and structuring systematic reviews of medical tests: utility of PICOTS PB - Analytic Frameworks CY - Decision Trees, and Other Frameworks ID - Samson2012 ER - TY - STD TI - Zhang L, Sheng J, Huang Y, Yang Y, Zhao H, Fang W, et al. Re-biopsy confers survival benefit through directing salvage treatment for patients failing prior EGFR-TKIs. Ann Oncol. 2016;27(suppl_6):2800118. https://doi.org/10.1093/annonc/mdw383.33 ID - ref13 ER - TY - JOUR AU - Singh, S. AU - Chang, S. M. AU - Matchar, D. B. AU - Bass, E. B. PY - 2012 DA - 2012// TI - Chapter 7: grading a body of evidence on diagnostic tests JO - J Gen Intern Med VL - 27 UR - https://doi.org/10.1007/s11606-012-2021-9 DO - 10.1007/s11606-012-2021-9 ID - Singh2012 ER - TY - JOUR AU - Presley, C. J. AU - Tang, D. AU - Soulos, P. R. AU - Chiang, A. C. AU - Longtine, J. A. AU - Adelson, K. B. PY - 2018 DA - 2018// TI - Association of Broad-Based Genomic Sequencing with Survival among Patients with Advanced non–Small Cell Lung Cancer in the community oncology setting JO - JAMA VL - 320 UR - https://doi.org/10.1001/jama.2018.9824 DO - 10.1001/jama.2018.9824 ID - Presley2018 ER - TY - STD TI - Lim SW, Park S, Kim Y, Cho JH, Park SE, Lee H, et al. Continuation of Gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung Cancer: a phase II single-arm trial. Lung Cancer. 2018. https://doi.org/10.1016/j.lungcan.2018.08.003. ID - ref16 ER - TY - JOUR AU - Hayden, J. A. AU - Côté, P. AU - Bombardier, C. PY - 2006 DA - 2006// TI - Evaluation of the quality of prognosis studies in systematic reviews JO - Ann Intern Med VL - 144 UR - https://doi.org/10.7326/0003-4819-144-6-200603210-00010 DO - 10.7326/0003-4819-144-6-200603210-00010 ID - Hayden2006 ER - TY - STD TI - Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. http://www.ncbi.nlm.nih.gov/pubmed/20332509. UR - http://www.ncbi.nlm.nih.gov/pubmed/20332509 ID - ref18 ER - TY - JOUR AU - Ghimire, S. AU - Kyung, E. AU - Lee, H. AU - Kim, E. PY - 2014 DA - 2014// TI - Oncology trial abstracts showed suboptimal improvement in reporting: a comparative before-and-after evaluation using CONSORT for abstract guidelines JO - J Clin Epidemiol VL - 67 UR - https://doi.org/10.1016/j.jclinepi.2013.10.012 DO - 10.1016/j.jclinepi.2013.10.012 ID - Ghimire2014 ER - TY - JOUR AU - Bossuyt, P. M. AU - Reitsma, J. B. AU - Bruns, D. E. AU - Gatsonis, C. A. AU - Glasziou, P. P. AU - Irwig, L. M. PY - 2003 DA - 2003// TI - The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration JO - Ann Intern Med VL - 138 UR - https://doi.org/10.7326/0003-4819-138-1-200301070-00012-w1 DO - 10.7326/0003-4819-138-1-200301070-00012-w1 ID - Bossuyt2003 ER - TY - JOUR AU - Schnipper, L. E. AU - Davidson, N. E. AU - Wollins, D. S. AU - Blayney, D. W. AU - Dicker, A. P. AU - Ganz, P. A. PY - 2016 DA - 2016// TI - Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.68.2518 DO - 10.1200/JCO.2016.68.2518 ID - Schnipper2016 ER -